Advert - Bayer

• Date posted
  01 November 2017
• Sanction
  Advertisement,
• Case number/s
  AUTH/2943/3/17 - Ex-employee of a service provider v Bayer

For producing representatives’ training and briefing material which suggested an unlicensed use for Xarelto (rivaroxaban), Bayer was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry.
Clause 9.1 - Failing to maintain high standards.
Clause 15.9 - Producing representatives’ briefing material that advocated a course of action likely to lead to a breach of the Code.